Status:
COMPLETED
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Advanced Solid Tumors
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
Eligibility Criteria
Inclusion
- Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
- Adequate coagulation, liver, and renal function.
- Candidate for DCE-MRI evaluations.
- ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
Exclusion
- Evidence of significant bleeding problems.
- History of certain gastrointestinal problems including fistula and abscess.
- Chronic, uncontrolled hypertension.
- Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00879684
Start Date
January 1 2008
End Date
April 1 2011
Last Update
January 26 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale Medical Imaging, Ltd.
Scottsdale, Arizona, United States, 85255
2
Premiere Oncology of Arizona
Scottsdale, Arizona, United States, 85258
3
Premiere Oncology, A Medical Corporation
Santa Monica, California, United States, 90404
4
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111